FATE THERAPEUTICS INC Proceeds from Stock Options Exercised
FATE THERAPEUTICS INC (FATE) reported Proceeds from Stock Options Exercised of $412.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2026-08-13
- FATE THERAPEUTICS INC proceeds from stock options exercised for the quarter ending 2025-12-31 was $0.00.
- FATE THERAPEUTICS INC proceeds from stock options exercised for the quarter ending 2025-09-30 was $0.00.
- FATE THERAPEUTICS INC proceeds from stock options exercised for the quarter ending 2025-06-30 was $0.00.
- FATE THERAPEUTICS INC proceeds from stock options exercised for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- FATE THERAPEUTICS INC proceeds from stock options exercised for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- FATE THERAPEUTICS INC proceeds from stock options exercised for fiscal 2024 was $295.00K, a 247.06% increase from fiscal 2023.
- FATE THERAPEUTICS INC proceeds from stock options exercised for fiscal 2023 was $85.00K, a 99.08% decline from fiscal 2022.
- FATE THERAPEUTICS INC proceeds from stock options exercised for fiscal 2022 was $9.21M, a 55.55% decline from fiscal 2021.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|
| 2026-06-30 | $412.00K 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-08-13 | $0.00 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2026-08-13 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | $0.00 derived: sum of 3 quarters · filed 2026-08-13 | $0.00 derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-13 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | -$4.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | -$4.00K derived: sum of 3 quarters · filed 2026-02-26 | $295.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$4.00K derived: sum of 2 quarters · filed 2025-11-13 | $295.00K 10-Q · filed 2025-11-13 | $115.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $295.00K 10-Q · filed 2025-08-12 | $115.00K derived: sum of 3 quarters · filed 2025-08-12 | $115.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $299.00K 10-Q · filed 2025-05-13 | $119.00K derived: sum of 2 quarters · filed 2025-05-13 | $119.00K derived: sum of 3 quarters · filed 2025-05-13 | $177.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$180.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | -$180.00K derived: sum of 2 quarters · filed 2025-03-05 | -$122.00K derived: sum of 3 quarters · filed 2025-03-05 | $85.00K 10-K · filed 2025-03-05 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $58.00K derived: sum of 2 quarters · filed 2024-11-12 | $265.00K 10-Q · filed 2024-11-12 | $1.78M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $58.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $265.00K 10-Q · filed 2024-08-13 | $1.78M derived: sum of 3 quarters · filed 2024-08-13 | $3.27M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $207.00K 10-Q · filed 2024-05-09 | $1.72M derived: sum of 2 quarters · filed 2024-05-09 | $3.21M derived: sum of 3 quarters · filed 2024-05-09 | $6.62M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $3.00M derived: sum of 2 quarters · filed 2024-02-26 | $6.41M derived: sum of 3 quarters · filed 2024-02-26 | $9.21M 10-K · filed 2024-02-26 |
| 2022-09-30 | $1.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $4.89M derived: sum of 2 quarters · filed 2023-11-08 | $7.69M 10-Q · filed 2023-11-08 | $11.14M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $3.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $6.20M 10-Q · filed 2023-08-08 | $9.65M derived: sum of 3 quarters · filed 2023-08-08 | $17.59M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $2.80M 10-Q · filed 2023-05-03 | $6.25M derived: sum of 2 quarters · filed 2023-05-03 | $14.19M derived: sum of 3 quarters · filed 2023-05-03 | $17.91M derived: sum of 4 quarters · filed 2023-05-03 |
| 2021-12-31 | $3.45M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $11.39M derived: sum of 2 quarters · filed 2023-02-28 | $15.11M derived: sum of 3 quarters · filed 2023-02-28 | $20.71M 10-K · filed 2023-02-28 |
| 2021-09-30 | $7.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $11.66M derived: sum of 2 quarters · filed 2022-11-03 | $17.27M 10-Q · filed 2022-11-03 | $22.15M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $3.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $9.32M 10-Q · filed 2022-08-03 | $14.21M derived: sum of 3 quarters · filed 2023-02-28 | $15.41M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $5.61M 10-Q · filed 2022-05-04 | $10.49M derived: sum of 2 quarters · filed 2023-02-28 | $11.69M derived: sum of 3 quarters · filed 2023-02-28 | $14.25M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $4.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $6.08M derived: sum of 2 quarters · filed 2023-02-28 | $8.64M derived: sum of 3 quarters · filed 2023-02-28 | $9.65M 10-K · filed 2023-02-28 |
| 2020-09-30 | $1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $3.76M derived: sum of 2 quarters · filed 2021-11-04 | $4.77M 10-Q · filed 2021-11-04 | $5.18M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $2.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $3.57M 10-Q · filed 2021-08-04 | $3.98M derived: sum of 3 quarters · filed 2022-02-28 | $4.15M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $1.01M 10-Q · filed 2021-05-05 | $1.42M derived: sum of 2 quarters · filed 2022-02-28 | $1.59M derived: sum of 3 quarters · filed 2022-02-28 | $2.27M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $413.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $576.00K derived: sum of 2 quarters · filed 2022-02-28 | $1.26M derived: sum of 3 quarters · filed 2022-02-28 | $2.52M 10-K · filed 2022-02-28 |
| 2019-09-30 | $163.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $851.00K derived: sum of 2 quarters · filed 2020-11-05 | $2.11M 10-Q · filed 2020-11-05 | $2.89M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $688.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $1.95M 10-Q · filed 2020-08-05 | $2.73M derived: sum of 3 quarters · filed 2021-02-24 | $3.86M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $1.26M 10-Q · filed 2020-05-11 | $2.04M derived: sum of 2 quarters · filed 2021-02-24 | $3.17M derived: sum of 3 quarters · filed 2021-02-24 | $3.35M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $779.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $1.91M derived: sum of 2 quarters · filed 2021-02-24 | $2.09M derived: sum of 3 quarters · filed 2021-02-24 | $2.69M 10-K · filed 2021-02-24 |
| 2018-09-30 | $1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $1.31M derived: sum of 2 quarters · filed 2019-11-05 | $1.91M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $175.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $781.00K 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | $606.00K 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | $205.00K 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |